Published in Diabetes Obes Metab on June 01, 2009
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care (2011) 1.61
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract (2009) 1.47
Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther (2014) 1.16
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf (2010) 1.10
Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol (2010) 1.06
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol (2012) 1.05
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes (2010) 0.98
Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev (2014) 0.94
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr (2012) 0.94
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid (2010) 0.92
Incretin agents in type 2 diabetes. Can Fam Physician (2010) 0.92
The alpha-cell as target for type 2 diabetes therapy. Rev Diabet Stud (2011) 0.91
The role of incretin therapy at different stages of diabetes. Rev Diabet Stud (2011) 0.89
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol (2014) 0.87
Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep (2016) 0.85
Incretin-based therapies: focus on effects beyond glycemic control alone. Diabetes Ther (2013) 0.84
The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol (2013) 0.83
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging (2013) 0.83
Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. Diabetes Ther (2016) 0.82
From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp Diabetes Res (2011) 0.82
Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag (2010) 0.82
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes (2011) 0.81
Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Ther (2011) 0.79
Diabetes: glycaemic control in type 2 (drug treatments). BMJ Clin Evid (2012) 0.78
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes Metab J (2016) 0.77
Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. Clin Diabetes (2014) 0.77
Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy. Diabetes Obes Metab (2016) 0.77
Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know. J Am Coll Cardiol (2016) 0.77
Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress. J Hum Hypertens (2014) 0.77
Saxagliptin for type 2 diabetes. Diabetes Metab Syndr Obes (2010) 0.77
Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. Adv Ther (2015) 0.77
Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors. Saudi Pharm J (2014) 0.77
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. Diabetes Metab Syndr Obes (2010) 0.77
Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes (2011) 0.77
Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vasc Health Risk Manag (2014) 0.76
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open (2017) 0.75
Saxagliptin and metformin in fixed combination for the treatment of type 2 diabetes in adults. Clin Med Insights Endocrinol Diabetes (2013) 0.75
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol (2015) 0.75
Saxagliptin efficacy. Diabetes Obes Metab (2010) 0.75
Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother (2011) 0.75
A dipeptidyl peptidase-4 inhibitor for adults with type 2 diabetes. P T (2010) 0.75
Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. Int J Clin Pract (2013) 0.75
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Adv Ther (2014) 0.75
Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. Vasc Health Risk Manag (2010) 0.75
Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. Eur J Clin Pharmacol (2014) 0.75
Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. Diabetes Metab Syndr Obes (2017) 0.75
Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes Ther (2017) 0.75
UMLS concept indexing for production databases: a feasibility study. J Am Med Inform Assoc (2001) 9.02
Organization of heterogeneous scientific data using the EAV/CR representation. J Am Med Inform Assoc (1999) 6.97
Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet (2001) 6.67
THE SYNTHESIS OF HEMOGLOBIN IN A CELL-FREE SYSTEM. Proc Natl Acad Sci U S A (1958) 4.92
Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ (1999) 4.66
Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage (2001) 4.48
GEM: a proposal for a more comprehensive guideline document model using XML. J Am Med Inform Assoc (2000) 4.46
Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease. Science (2000) 4.22
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA (1997) 4.09
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol (1999) 3.99
Pupil-led sex education in England (RIPPLE study): cluster-randomised intervention trial. Lancet (2004) 3.86
Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell (1998) 3.72
Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol (2000) 3.53
Distinct actions of cis and trans ATP within the double ring of the chaperonin GroEL. Nature (1997) 3.48
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
Application of operant conditioning procedures to the behavior problems of an autistic child: a follow-up and extension. Behav Res Ther (1967) 3.23
Structure and function in GroEL-mediated protein folding. Annu Rev Biochem (1998) 3.18
Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 3.08
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med (1989) 3.02
Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol (1996) 2.68
American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med (2000) 2.67
Primary structure of major outer membrane protein II (ompA protein) of Escherichia coli K-12. Proc Natl Acad Sci U S A (1980) 2.64
Primary structure of major outer membrane protein I of Escherichia coli B/r. Proc Natl Acad Sci U S A (1979) 2.60
IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther (2000) 2.59
The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg (2000) 2.56
Lipid-binding proteins: a family of fatty acid and retinoid transport proteins. Adv Protein Chem (1994) 2.53
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 2.52
Craniopagus parasiticus. Everard Home's Two-Headed Boy of Bengal and some other cases. Surg Neurol (1989) 2.50
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci (1998) 2.48
Recovery of human ova from the uterine tubes. J Am Med Assoc (1928) 2.43
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) (2005) 2.37
Mirror movements in parkinsonism: evaluation of a new clinical sign. J Neurol Neurosurg Psychiatry (2005) 2.35
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology (2012) 2.34
Cerebral arteriovenous oxygen difference as an estimate of cerebral blood flow in comatose patients. J Neurosurg (1989) 2.32
Lower BMI cut-off value to define obesity in Hong Kong Chinese: an analysis based on body fat assessment by bioelectrical impedance. Br J Nutr (2001) 2.25
A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant (2012) 2.25
Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods (2001) 2.22
A dynamic model for the allosteric mechanism of GroEL. J Mol Biol (2000) 2.20
Peptidoglycan recognition proteins: a novel family of four human innate immunity pattern recognition molecules. J Biol Chem (2001) 2.18
Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease. Neurology (2012) 2.18
Very short patch mismatch repair in phage lambda: repair sites and length of repair tracts. Genetics (1986) 2.17
Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A (1994) 2.14
Simultaneous bilateral laser in situ keratomileusis: safety and efficacy. Ophthalmology (1999) 2.13
Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci U S A (1995) 2.12
The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med (1996) 2.11
The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP). Heart (2007) 2.06
Complete amino acid sequence and glycosylation sites of glycoprotein gp71A of Friend murine leukemia virus. Proc Natl Acad Sci U S A (1982) 2.06
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr (2001) 2.02
An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell (2000) 2.00
Cloning and expression of steroid sulfatase cDNA and the frequent occurrence of deletions in STS deficiency: implications for X-Y interchange. Cell (1987) 1.99
Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J Virol (1995) 1.99
DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res (2000) 1.97
Radioimmunological screening method for specific membrane proteins. Anal Biochem (1979) 1.96
Tuberculosis in young adults and the elderly. A prospective comparison study. Chest (1994) 1.94
Interactions between two different inhibitory systems in the human motor cortex. J Physiol (2001) 1.91
An apoptosis-inducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild-type and homozygous mutants. Hum Genet (1997) 1.88
Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care (1999) 1.87
Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A (1995) 1.86
A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J Neurosci Methods (2001) 1.86
Reactions of electron-deficient alkynes and allenes under phosphine catalysis. Acc Chem Res (2001) 1.86
Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology (1993) 1.83
Neurofilaments are obligate heteropolymers in vivo. J Cell Biol (1993) 1.82
TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene (2010) 1.81
Perceptual correlates of neural representations evoked by odorant enantiomers. J Neurosci (2001) 1.81
Parents explain more often to boys than to girls during shared scientific thinking. Psychol Sci (2001) 1.81
Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA (1997) 1.78
Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. Am J Respir Cell Mol Biol (2001) 1.78
MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics (1997) 1.77
The influence of John Hunter's inoculation practice on Edward Jenner's discovery of vaccination against smallpox. J R Soc Med (1990) 1.76
THE INCORPORATION OF AMINO ACIDS INTO RIBONUCLEIC ACID. Proc Natl Acad Sci U S A (1958) 1.75
Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation (1995) 1.73
Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab (2006) 1.71
Complications of laparoscopic procedures after concentrated training in urological laparoscopy. J Urol (2001) 1.71
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
DRBP76, a double-stranded RNA-binding nuclear protein, is phosphorylated by the interferon-induced protein kinase, PKR. J Biol Chem (1999) 1.70
Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med (2000) 1.70
Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther (1999) 1.67
Dextromethorphan decreases the excitability of the human motor cortex. Neurology (1998) 1.66
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett (1999) 1.62
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin (2009) 1.62
Malignant and Non-malignant Uterine and Vaginal Lesions in Mice Receiving Estrogens and Estrogens and Androgens Simultaneously. Yale J Biol Med (1939) 1.61
A clone-array pooled shotgun strategy for sequencing large genomes. Genome Res (2001) 1.60
Involvement of the human pedunculopontine nucleus region in voluntary movements. Neurology (2010) 1.60
Involvement of the human subthalamic nucleus in movement preparation. Neurology (2003) 1.59
Transcranial magnetic stimulation for the treatment of seizures: a controlled study. Neurology (2002) 1.59
Non-invasive pulsed cavitational ultrasound for fetal tissue ablation: feasibility study in a fetal sheep model. Ultrasound Obstet Gynecol (2011) 1.59
The nucleotide sequence of Saccharomyces cerevisiae chromosome XVI. Nature (1997) 1.58
Intracellular Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in buccal epithelial cells collected from human subjects. Infect Immun (2001) 1.58
PapD chaperone function in pilus biogenesis depends on oxidant and chaperone-like activities of DsbA. Proc Natl Acad Sci U S A (1994) 1.58
cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene (2007) 1.58
A novel insulin formulation with a more rapid onset of action. Diabetologia (2008) 1.57
Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology (1991) 1.57
The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol (2001) 1.54
Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart (2006) 1.53